Novartis to test autoimmune disease drug in Covid-19 pneumonia patients
The Swiss drugmaker said Tuesday it would initiate a Phase III trial of 450 patients to test Ilaris as a treatment for cytokine release syndrome in Covid-19 pneumonia patients.
The Swiss drugmaker said Tuesday it would initiate a Phase III trial of 450 patients to test Ilaris as a treatment for cytokine release syndrome in Covid-19 pneumonia patients.